Conditions: Asthma
Keywords: Asthma Staged withdrawal of background therapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.

Detailed description:
Study terminated on 7th April 2015. The termination was due to business reasons. No safety or efficacy concerns contributed to the termination of the study

Arms:
arm 1: Matched blinded placebo arm 2: PF-03715455

Interventions: intervention 1: Placebo intervention 2: PF-03715455
Intervention descriptions: intervention 1: 680 micrograms BID, Orally inhaled placebo for 12 weeks intervention 2: 680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks

Protocol document: